1.
Cancers (Basel)
; 14(17)2022 Aug 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36077792
RESUMO
The era of personalized cancer therapy is here. Advances in the field of immunotherapy have paved the way for the development of individualized neoantigen-based therapies that can translate into favorable treatment outcomes and fewer side effects for patients. Addressing challenges related to the identification, access, and clinical application of neoantigens is critical to accelerating the development of individualized immunotherapy for cancer patients.